SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA)

Josep M. Llibre,[1] Carlos Alves Brites,[2] Chien-Yu Cheng,[3,4] Olayemi Osiyemi,[5] Carlos Galera,[6] Laurent Hocqueloux,[7] Franco Maggiolo,[8] Olaf Degen,[9] Libby Blair,[10] Brian Wynne,[10] James Oyee,[11] Mark Underwood,[10] Lloyd Curtis,[11] Gilda Bontempo,[10] Jean van Wyk[12]

[1]Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; [2]Universidade Federal da Bahia, Salvador, Brazil; [3]Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; [4]School of Public Health, National Yang-Ming University, Taipei, Taiwan; [5]Triple O Research Institute PA, West Palm Beach, FL, USA; [6]Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; [7]Centre Hospitalier Régional d'Orléans, Orléans, France; [8]ASST Papa Giovanni XXIII, Bergamo, Italy; [9]Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; [10]ViiV Healthcare, Research Triangle Park, NC, USA; [11]GlaxoSmithKline, Uxbridge, UK; [12]ViiV Healthcare, Brentford, UK

11th IAS Conference on HIV Science; July 18-21, 2021; Virtual

Disclosures

- Josep M. Llibre has received honoraria or consultation fees from and participated in company-sponsored speakers bureaus for ViiV Healthcare, Gilead Sciences, and Janssen-Cilag

Introduction

- 2DRs have reduced the number of antiretroviral agents taken by individuals who need lifelong ART[1]
- DTG/3TC has demonstrated long-term non-inferior efficacy, a good safety profile, and a high barrier to resistance through Week 144 in treatment-naive individuals in the GEMINI studies (vs DTG + TDF/FTC)[2-4] and treatment-experienced, virologically suppressed individuals in the TANGO study (vs continuing TAF-based regimens)[5-7]

GEMINI-1 and GEMINI-2, Week 144
Virologic Outcomes (Snapshot)[4]



TANGO, Week 144
Virologic Outcomes (Snapshot)[7]



1. Back. *Germs*. 2017;7:113-114. **2.** Cahn et al. *Lancet*. 2019;393:143-155. **3.** Cahn et al. *J Acquir Immune Defic Syndr.* 2020;83:310-318. **4.** Cahn et al. HIV Glasgow 2020; Virtual. Poster P018. **5.** van Wyk et al. *Clin Infect Dis*. 2020;71:1920-1929. **6.** van Wyk et al. HIV Glasgow 2020; Virtual. Slides O441. **7.** van Wyk et al. IAS 2021; Virtual. Poster PEB164.

Introduction (cont)

- The TANGO study included only individuals treated with TAF-based regimens, mostly EVG/c/TAF/FTC and RPV/TAF/FTC[1]
- To broaden the scope of data beyond comparison with TAF-based regimens (TANGO), the objective of SALSA was to evaluate efficacy and safety of switching to the 2-drug regimen of DTG/3TC FDC compared with continuing any current 3- or 4-drug ART regimen (CAR) in adults with HIV-1 over 48 weeks

1. van Wyk et al. *Clin Infect Dis*. 2020;71:1920-1929.

SALSA Phase III Study Design

Randomized, open-label, active-controlled, multicenter, parallel-group, non-inferiority study



[a]Stratified by baseline third agent class (PI, INSTI, or NNRTI). [b]5% non-inferiority margin.

Demographics and Baseline Characteristics: ITT-E Population

Characteristic	DTG/3TC (N=246)	CAR (N=247)
Age		
Median (range), y	45 (22-74)	45 (23-83)
Age ≥50 y, n (%)	98 (40)	95 (38)
Female, n (%)	108 (44)	84 (34)
Race, n (%)		
African American/African heritage	45 (18)	48 (19)
Asian	31 (13)	39 (16)
White	149 (61)	144 (58)
CD4+ cell count, median (range), cells/mm^3	675 (154-2089)	668 (94-1954)
CD4+ cell count, cells/mm^3, n (%)		
<350	21 (9)	17 (7)
≥350	224 (91)	230 (93)
Duration of ART before Day 1, median (range), mo	63 (4-240)	71 (12-253)
Baseline third agent class, n (%)		
INSTI	98 (40)	98 (40)
NNRTI	123 (50)	124 (50)
PI	25 (10)	25 (10)
NRTIs received at screening in ≥30% of participants		
FTC	149 (61)	156 (63)
TDF[a]	109 (44)	109 (44)
3TC	96 (39)	89 (36)
TAF	83 (34)	91 (37)
Weight, median (range), kg	73 (43-154)	75.0 (36-160)
BMI, median (range), kg/m^2	25 (17-51)	26 (14-69)

[a]Includes tenofovir disoproxil succinate (DTG/3TC, n=1; CAR, n=3).

DTG/3TC Is Non-Inferior to CAR at Week 48

Virologic outcomes (Snapshot analysis)



Adjusted treatment difference (95% CI)[b]



HIV-1 RNA ≥50 c/mL
DTG/3TC is non-inferior to CAR at Week 48 based on a 5% non-inferiority margin



HIV-1 RNA <50 c/mL
DTG/3TC is non-inferior to CAR at Week 48 based on a −12% non-inferiority margin

- In the per-protocol population, 1/222 (0.5%) in the DTG/3TC group and 3/234 (1.3%) in the CAR group had HIV-1 RNA ≥50 c/mL at Week 48 (adjusted difference, −0.8%; 95% CI, −2.5% to 0.9%)

[a]Primary endpoint (Snapshot virologic non-response, ITT-E). [b]Based on Cochran-Mantel-Haenszel stratified analysis (DTG/3TC − CAR) adjusting for baseline third agent class.

Snapshot Outcomes at Week 48: ITT-E Population

n (%)	DTG/3TC (N=246)	CAR (N=247)
HIV-1 RNA <50 c/mL	232 (94)	229 (93)
HIV-1 RNA ≥50 c/mL	1 (<1)	3 (1)
Data in window and HIV-1 RNA ≥50 c/mL	1 (<1)[a]	1 (<1)[b]
Discontinued for lack of efficacy	0	2 (<1)
Discontinued for other reason and HIV-1 RNA ≥50 c/mL	0	0
Change in ART	0	0
No virologic data	13 (5)	15 (6)
Discontinued because of AE or death[c]	5 (2)	2 (<1)
Discontinued for other reasons[d]	7 (3)	10 (4)
On study but missing data in window[e]	1 (<1)	3 (1)

[a]1 participant had VL of 53 c/mL at Week 48, followed by 2 retests and was withdrawn with VL <40 c/mL after Week 52. [b]1 participant had VL of 90 c/mL at Week 36 and was withdrawn during Week 48 window with VL of 68 c/mL. [c]Reasons for discontinuations due to AEs in DTG/3TC group: insomnia (n=2), alcohol abuse/anxiety (n=1), weight increased (n=1), and unknown cause of death (n=1); in CAR group: ulcerative colitis and post-operative complications (n=1 each); last on-treatment VLs were all <50 c/mL. [d]Other reasons for discontinuation included protocol deviation (n=6), participant withdrawal (n=6), pregnancy (n=2), physician decision (n=2), and lost to follow-up (n=1). [e]Missing data in window was due to COVID-19 pandemic in 2 participants in the CAR group only.

Confirmed Virologic Withdrawals Through Week 48

Confirmed virologic withdrawal (CVW), n (%)	DTG/3TC (N=246)	CAR (N=247)
Week 48	0	0

- Zero resistance mutations were observed as zero participants met confirmed virologic withdrawal criteria

Confirmed virologic withdrawal criteria defined as one assessment of HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL.

Summary of Adverse Events and Weight Changes Through Week 48: Safety Population

n (%)	DTG/3TC (N=246)	CAR (N=247)
Any AE	180 (73)	172 (70)
AEs occurring in ≥7% of participants in either group		
Headache	16 (7)	17 (7)
Weight increased	20 (8)	5 (2)
Any grade 2-5 AE	88 (36)	105 (43)
Grade 2-5 AEs occurring in ≥3% of participants in either group		
COVID-19	7 (3)	4 (2)
Headache	1 (<1)	9 (4)
Syphilis	7 (3)	1 (<1)
Drug-related AEs	48 (20)	16 (6)
Drug-related AEs occurring in ≥3% of participants in either group		
Weight increased	14 (6)	0
Insomnia	7 (3)	1 (<1)
Dizziness	7 (3)	0
AEs leading to withdrawal from the study	5 (2)	3 (1)
Drug-related AEs leading to withdrawal from the study	4 (2)	1 (<1)
Any SAE	7 (3)	16 (6)
Drug-related SAEs	0	0

Data in the table are cumulative through Week 48.

- Adjusted mean change in weight from baseline to Week 48 was 2.1 kg in the DTG/3TC group and 0.6 kg in the CAR group
- Adjusted mean change in BMI from baseline to Week 48 was 0.7 kg/m^2 in the DTG/3TC group and 0.2 kg/m^2 in the CAR group

Llibre et al. IAS 2021; Virtual. Slides OALB0303.

Adverse Events Leading to Withdrawal Through Week 48: Safety Population

n (%)	DTG/3TC (N=246)	CAR (N=247)
AEs leading to withdrawal from the study	5 (2)	3 (1)
Psychiatric	3 (1)	1 (<1)
Insomnia	2 (<1)	0
Alcohol abuse	1 (<1)	0
Anxiety	1 (<1)	0
Suicidal ideation	0	1 (<1)
Gastrointestinal disorders	0	1 (<1)
Colitis ulcerative[a]	0	1 (<1)
General disorders and administration site conditions	1 (<1)	0
Death[a]	1 (<1)	0
Injury, poisoning, and procedural complications	0	1 (<1)
Post-procedural complication[a]	0	1 (<1)
Investigations	1 (<1)	0
Weight increased	1 (<1)	0

[a]Considered unrelated to study treatment.

Llibre et al. IAS 2021; Virtual. Slides OALB0303.

Change in Renal Biomarkers at Week 48: Safety Population



- Similar small changes in eGFR from cystatin C were observed in both treatment groups; decreases in eGFR by creatinine were observed in both treatment groups, with a greater decrease with DTG/3TC
- Improvements in markers for proximal tubular renal function were observed with DTG/3TC

Adjusted mean treatment difference (95% CI) displayed above treatment groups.
[a]Estimated mean change from baseline at Week 48 in each group calculated from MMRM adjusting for treatment, visit, baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, BMI (continuous), presence of diabetes mellitus, presence of hypertension, baseline biomarker value (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor. [b]Based on estimated geometric means ratio of Week 48 vs baseline. Based on the same model as plasma/serum markers except adjusting for $\log_e$-transformed baseline biomarker value. n = number of participants with non-missing data at baseline and Week 48.

Change in Bone Biomarkers at Week 48: Safety Population



- Improvements in markers of bone turnover were observed after switching to DTG/3TC

Adjusted mean treatment difference (95% CI) displayed above treatment groups.
[a]Estimated mean change from baseline at Week 48 in each group calculated from MMRM adjusting for treatment, visit, baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, BMI (continuous), smoking status, baseline biomarker value (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor.

Change in Serum Lipids at Week 48: Safety Population



- Small and similar changes between treatment groups were observed at Week 48 across lipid parameters

Adjusted mean treatment difference (95% CI) displayed above treatment groups.
[a]n = number of participants with non-missing fasting lipid data at baseline and Week 48, removing those with lipid-modifying agent administered at baseline (lipid data collected after initiation of a lipid-modifying agent were censored and multiple imputation was applied). [b]Percent change from baseline based on adjusted ratio (Week 48 to baseline) in each group calculated from a multiple imputation model applied to change from baseline in $\log_e$-transformed data adjusting for treatment, visit, baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, $\log_e$-transformed baseline value (continuous), treatment-by-visit interaction, and $\log_e$-transformed baseline value-by-visit interaction, with visit as the repeated factor.

Change in Inflammatory Biomarkers at Week 48: Safety Population



MMRM analysis was not performed for D-dimer due to high proportion of participants with D-dimer < LLQ in both treatment groups. Baseline geometric mean values (DTG/3TC group; CAR group): C-reactive protein (1.34; 1.27), interleukin-6 (1.73; 1.68), soluble CD14 (1.55×10^6; 1.46×10^6), and soluble CD163 (538.18; 541.70).

[a]Ratio is the estimated adjusted ratio (Week 144 to baseline) in each group calculated using MMRM applied to change from baseline in $\log_e$-transformed data adjusting for treatment, visit, baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, BMI (continuous), smoking status, HCV co-infection status, $\log_e$-transformed baseline biomarker value (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor.

Conclusions

- Switching to DTG/3TC FDC in virologically suppressed adults on a 3- or 4-drug regimen demonstrated non-inferior virologic efficacy to a variety of ART regimens through 48 weeks of treatment
- Zero confirmed virologic withdrawals were observed in either treatment group, with no viral resistance
- DTG/3TC FDC had a good safety and tolerability profile through Week 48
  - Rate of AEs leading to study withdrawal was low in both treatment groups; a higher rate of drug-related AEs was observed in the DTG/3TC group, as expected with an open-label switch study
  - Changes in proximal tubular renal function and bone biomarkers favored the DTG/3TC group, whereas changes in eGFR by cystatin C and lipids were similar between treatment groups; changes in inflammatory biomarkers were also generally similar between groups, with the exception of soluble CD14 changes favoring DTG/3TC
- These data build upon the previous TANGO study and support DTG/3TC as a robust switch option with high levels of efficacy, good safety and tolerability, and a high barrier to resistance

Acknowledgments

- We thank the study participants; their families and caregivers; investigators and site staff who participated in the study; and the ViiV Healthcare, GlaxoSmithKline, and Pharmaceutical Product Development study team members

Argentina
Cahn
Lopardo
Lupo
Porteiro

Belgium
De Wit
Florence
Vandekerckhove

Brazil
Alvezs
Diaz
Gomes de Silva
Grinsztejn
Guimaraes de Lacerda
Lima
Souza

Canada
Angel
de Wet
Kasper
Routy
Sasseville
Walmsley
Wong

China
Chen
Li
Lu
Wu
Zhang

Denmark
Benfield
Gerstoft
Johansen
Laursen

France
Ajana
Bonnet
Bouchaud
Delobel
Hocqueloux
Lacombe
Molina
Pugliese

Germany
Bogner
Degen
Esser
Jonsson-Oldenbutte
Lutz
Rockstroh
Scholten
Spinner
Stellbrink
Wyen

Italy
Antinori
Castelli
Castagna
d'Arminio Montforte
Di Giambenedetto
Gulminetti
Lazzarin
Maggiolo
Mussini
Rizzardini

Mexico
Amaya Tapia
Andrade Villanueva
Perez Rios
Santoscoy Gomez

Russia
Chernova
Ryamova
Voronin

South Africa
Kaplan
Lombaard
van Schalkwyk

Spain
Castro Iglesias
De Los Santos Gil
Espinosa Aguilera
Galera
Garcia Deltoro
Giron
Gonzales Garcia
Hayek Peraza
Hernandez-Quero
Llibre Codina
Lopez Bernaldo de Quiros
Moreno Guillen
Perez Valero
Raya Cruz
Rubio
Suarez

Sweden
Brannstrom
Flamholc
Gisslen
Thalme

Taiwan
Cheng
Hung
Lu
Tsai
Wang
Yang

UK
Boffito
Clarke A
Clarke E
Gompels
Greig
Hunter
Lewthwaite
Pett
Schembri
Taylor
Ustianowski

USA
Clough
Cook
Frank
Hagins
Hodder
Hodge
Homans
Kumar
Luetkemeyer
Nahass
Ogbuagu
Osiyemi
Parks
Salazar
Whitehead
Zurawski

ViiV Healthcare